Discovery of PF-06855800, a SAM competitive PRMT5 inhibitor with potent antitumor activity

被引：4

作者：

Mcalpine, Indrawan J. ^{[1
]}

Tatlock, John ^{[1
]}

Billitti, Joseph ^{[1
]}

Braganza, John ^{[1
]}

Brooun, Alexei ^{[1
]}

Deng Ya-Li ^{[1
]}

Hirakawa, Brad ^{[1
]}

Jensen-Pergakes, Kristen ^{[1
]}

Kumpf, Robert ^{[1
]}

Liu, Wei ^{[1
]}

Maegley, Karen ^{[1
]}

McTigue, Michele ^{[1
]}

Patman, Ryan ^{[1
]}

Rui, Eugene ^{[1
]}

Scales, Stephanie ^{[1
]}

Spiegel, Noah ^{[1
]}

Tran-Dube, Michelle ^{[1
]}

Wang, Fen ^{[1
]}

Wang, Zhenxiong ^{[1
]}

Yamazaki, Shinji ^{[1
]}

Zhang, Tao ^{[1
]}

Wythes, Martin ^{[1
]}

机构：

[1] Pfizer Global R&D, San Diego, CA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-4857

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4857

引用

页数：2

共 50 条

[31] JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models
Wu, Tongfei
Millar, Hillary
Gaffney, Dana
Beke, Lijs
Mannens, Geert
Vinken, Petra
Sommers, Ivan
Thuring, Jan-Willem
Sun, Weimei
Moy, Christopher
Pande, Vineet
Zhou, Junguo
Haddish-Berhane, Nahor
Salvati, Mark
Laquerre, Sylvie
Lorenzi, Matthew V.
Brehmer, Dirk
CANCER RESEARCH, 2018, 78 (13)
[32] Discovery of Potent Heterodimeric Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Sustained Antitumor Activity
Perez, Heidi L.
Chaudhry, Charu
Emanuel, Stuart L.
Fanslau, Caroline
Fargnoli, Joseph
Gan, Jinping
Kim, Kyoung S.
Lei, Ming
Naglich, Joseph G.
Traeger, Sarah C.
Vuppugalla, Ragini
Wei, Donna D.
Vite, Gregory D.
Talbott, Randy L.
Borzilleri, Robert M.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (03) : 1556 - 1562
[33] Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss
Fedoriw, Andrew
Rajapurkar, Satyajit R.
O'Brien, Shane
Gerhart, Sarah V.
Mitchell, Lorna H.
Adams, Nicholas D.
Rioux, Nathalie
Lingaraj, Trupti
Ribich, Scott A.
Pappalardi, Melissa B.
Shah, Niyant
Laraio, Jenny
Liu, Yan
Butticello, Michael
Carpenter, Chris L.
Creasy, Caretha
Korenchuk, Susan
McCabe, Michael T.
McHugh, Charles F.
Nagarajan, Raman
Wagner, Craig
Zappacosta, Francesca
Annan, Roland
Concha, Nestor O.
Thomas, Roberta A.
Hart, Timothy K.
Smith, Jesse J.
Copeland, Robert A.
Moyer, Mikel P.
Campbell, John
Stickland, Kim
Mills, James
Jacques-O'Hagan, Suzanne
Allain, Christina
Johnston, Danielle
Raimondi, Alejandra
Scott, Margaret Porter
Waters, Nigel
Swinger, Kerren
Boriack-Sjodin, Ann
Riera, Tom
Shapiro, Gideon
Chesworth, Richard
Prinjha, Rabinder K.
Kruger, Ryan G.
Barbash, Olena
Mohammad, Helai P.
CANCER CELL, 2019, 36 (01) : 100 - +
[34] PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands
Mishra, Vasudha
Singh, Alka
Korzinkin, Michael
Cheng, Xiangying
Wing, Claudia
Sarkisova, Viktoria
Koppayi, Ashwin L.
Pogorelskaya, Alexandra
Glushchenko, Oksana
Sundaresan, Manu
Thodima, Venkat
Carter, Jack
Ito, Koichi
Scherle, Peggy
Trzcinska, Anna
Ozerov, Ivan
Vokes, Everett E.
Cole, Grayson
Pun, Frank W.
Shen, Le
Miao, Yuxuan
Pearson, Alexander T.
Lingen, Mark W.
Ruggeri, Bruce
Rosenberg, Ari J.
Zhavoronkov, Alex
Agrawal, Nishant
Izumchenko, Evgeny
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
[35] Structure-Based Discovery and Biological Assays of a Novel PRMT5 Inhibitor for Non-Small Cell Lung Cancer
Chen, Yingqing
Zhang, Mingyu
Wu, Anxin
Yao, Xiaojun
Wang, Qianqian
MOLECULES, 2022, 27 (21):
[36] First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies
Smith, J.
Urosevic, J.
Moore, S.
Magiera, L.
Bradshaw, L.
Gianni, D.
Srinivasan, B.
Debreczeni, J.
Stubbs, C.
Vazquez-Chantada, M.
Hong, T.
Cronin, A.
Khan, K.
Wiseman, E.
Ferguson, D.
Lynch, J.
Chan, H. M.
Critchlow, S.
Fawell, S.
Dean, E.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S59 - S60
[37] The MTAcooperative PRMT5 inhibitor AM9747 exhibits robust antitumor activity in combination with clinically relevant chemotherapies and targeted agents in MTAP null tumor models
Slemmons, Katherine
Belmontes, Brian
Liu, Siyuan
Moriguchi, Jodi
Policheni, Antonia
Hughes, Paul E.
CANCER RESEARCH, 2023, 83 (07)
[38] Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization
Mao, Ruifeng
Shao, Jingwei
Zhu, Kongkai
Zhang, Yuanyuan
Ding, Hong
Zhang, Chenhua
Shi, Zhe
Jiang, Hualiang
Sun, Dequn
Duan, Wenhu
Luo, Cheng
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (14) : 6289 - 6304
[39] Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors
Chen, Yuting
Shi, Qiongyu
Yang, Hong
Li, Jiayi
Zhou, Kaixin
Zhang, Junjie
Wang, Zekun
Shi, Huanyu
Xiong, Bing
Liu, Jia
Huang, Xun
Liu, Tongchao
BIOORGANIC CHEMISTRY, 2023, 130
[40] Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity
Chen, Weilin
Chen, Xin
Li, Dongdong
Wang, Xianghan
Long, Guanlu
Jiang, Zhengyu
You, Qidong
Guo, Xiaoke
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223

← 1 2 3 4 5 →